Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications

Area of Science:

• Cardiology
• Pharmacology

Background:

• Increased heart rate (HR) poses risks in various diseases, notably chronic heart failure (CHF).
• Managing CHF remains challenging despite medical advancements, with significant hospitalization burdens and healthcare costs.
• Current treatments for CHF face limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review the efficacy and safety of ivabradine in managing cardiovascular conditions.
• To explore ivabradine's role in reducing heart rate and improving clinical outcomes.
• To assess ivabradine's utility in patients with contraindications or intolerance to beta-blockers.

Main Methods:

• Selective inhibition of the cardiac pacemaker I(f) ionic current by ivabradine.
• Analysis of clinical studies demonstrating ivabradine's impact on HR, clinical outcomes, and quality of life.
• Review of ivabradine's application in conditions beyond CHF, including ischemic heart disease and sepsis.

Main Results:

• Ivabradine substantially lowers HR without affecting intracardiac conduction, contractility, or ventricular repolarization.
• Clinical studies show ivabradine improves quality of life and reduces the risk of death from heart failure or cardiovascular causes.
• Updated guidelines recommend ivabradine for reducing heart failure hospitalizations.

Conclusions:

• Ivabradine is a valuable therapeutic option for heart rate reduction in various cardiovascular conditions.
• Its safety and efficacy profile supports its use, especially in patients unable to tolerate beta-blockers.
• Ivabradine offers a promising strategy to mitigate risks associated with elevated heart rate and improve patient outcomes.